As the role of HER2-low status in predicting the response to chemotherapy remains controversial, with inconsistent findings between operable and advanced breast cancer patients, the treatment landscape for HER2-negative advanced breast cancer, especially in the Chinese population, needs further clarification. This evidence concerns the gene ERBB2 and breast cancer.